We are 217,836 members in 81 forums discussing 154,335 topics.

Help with Abbreviations

Topic: Breaking Research News from sources other than breastcancer.org

Forum: Clinical Trials, Research News, Podcasts, and Study Results —

Share your research articles, interpretations and experiences here. Let us know how these studies affect you and your decisions.

Posted on: Nov 21, 2017 12:31AM - edited Nov 21, 2017 12:35AM by Lumpie

Lumpie wrote:

I watch for research news on breast cancer, treatments, etc., and frequently see interesting articles. There is a topic on BCO called "Breaking Research News from Breastcancer.org." One of the moderators suggested that another topic might be appropriate for posting links and synopses of reports on research found elsewhere. So here it is! Please post links to reports on research form reliable sources. Thanks for sharing!

"We must be willing to let go of the life we have planned, so as to have the life that is waiting for us." "If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride." Dx 2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC) Chemotherapy 1/13/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Targeted Therapy 1/14/2016 Herceptin (trastuzumab) Dx 2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+ Radiation Therapy Whole-breast: Breast Surgery Lumpectomy: Right Surgery Lumpectomy: Right
Log in to post a reply

Page 29 of 32 (935 results)

Posts 841 - 870 (935 total)

Log in to post a reply

Feb 11, 2019 10:25PM - edited Feb 11, 2019 10:33PM by Lumpie

Roche Adapts Newer Breast Cancer Drug in Face of Herceptin Imitations

Roche aims to broaden the use of Kadcyla (ado-trastuzumab emtansine) for breast cancer as rivals crowd into the market with biosimilar copies of its older mainstay Herceptin (trastuzumab).

Roche said on Tuesday it had applied for U.S. Food and Drug Administration approval for Kadcyla, a five-year-old drug, for post-surgical use in women with a form of early stage breast cancer who still show signs of disease after treatment with Herceptin and chemotherapy.

"With Kadcyla, the approximately 60 percent share of sales generated by Herceptin as an adjuvant would be secured for several years..."

Of people treated with Kadcyla, 88.3 percent did not see their breast cancer return after three years - compared to 77 percent treated after surgery with Herceptin - according to a clinical study Roche is using to underpin its approval case with the FDA.

The FDA has granted the medicine a speedy review, Roche said, pointing to a decision in coming months.

https://www.medscape.com/viewarticle/908679

"We must be willing to let go of the life we have planned, so as to have the life that is waiting for us." "If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride." Dx 2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC) Chemotherapy 1/13/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Targeted Therapy 1/14/2016 Herceptin (trastuzumab) Dx 2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+ Radiation Therapy Whole-breast: Breast Surgery Lumpectomy: Right Surgery Lumpectomy: Right
Log in to post a reply

Feb 11, 2019 10:45PM Lumpie wrote:

Half a Million Breast Cancer Deaths Avoided in Last 30 Years Encouraging Statistics Are a Result of Improved Treatment and Screening

Progress in both detection and management of breast cancer may have saved the lives of hundreds of thousands of women over the past three decades, according to a new report.

https://www.medscape.com/viewarticle/908920#vp_1

https://onlinelibrary.wiley.com/doi/epdf/10.1002/c...

Cancer 2019;0:1-7

"We must be willing to let go of the life we have planned, so as to have the life that is waiting for us." "If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride." Dx 2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC) Chemotherapy 1/13/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Targeted Therapy 1/14/2016 Herceptin (trastuzumab) Dx 2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+ Radiation Therapy Whole-breast: Breast Surgery Lumpectomy: Right Surgery Lumpectomy: Right
Log in to post a reply

Feb 12, 2019 10:49PM Lumpie wrote:

Calif. Physician Indicted in Alleged Cancer Drug Scam Benedict Liao, MD, was featured in earlier MedPage Today investigation by John Fauber, Reporter, Milwaukee Journal Sentinel/MedPage TodayFebruary 08, 2019

A physician who was the subject of a 2018 Milwaukee Journal Sentinel/MedPage Todayinvestigation has been indicted by federal prosecutors as part of an alleged $1.6-million scheme to sell an unapproved cancer drug to patients around the country.

https://www.medpagetoday.com/publichealthpolicy/et...


"We must be willing to let go of the life we have planned, so as to have the life that is waiting for us." "If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride." Dx 2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC) Chemotherapy 1/13/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Targeted Therapy 1/14/2016 Herceptin (trastuzumab) Dx 2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+ Radiation Therapy Whole-breast: Breast Surgery Lumpectomy: Right Surgery Lumpectomy: Right
Log in to post a reply

Feb 12, 2019 10:53PM Lumpie wrote:

iMedicalApps: Medicare's 'What's Covered' Review Unravel the mysteries of Medicare on your mobile device

In January, the Centers for Medicare and Medicaid Services (CMS) launched a new app called "What's covered." The app takes some of the most popular information from the Medicare website and puts it in the palm of patients and providers hands via an intuitive app.

The primary focus for the app is on the common "what's covered" preventive services questions....The app contains key information on both Part A and Part B coverage and the prices for what is/isn't covered in those two areas....The app emphasizes those preventive services that are or are not covered (such as USPSTF recommendations) and both hospital and outpatient information. All data is available on the Medicare website, but the app is more user-friendly regarding Medicare -- what's covered.

https://www.medpagetoday.com/blogs/iltifathusain/7...



"We must be willing to let go of the life we have planned, so as to have the life that is waiting for us." "If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride." Dx 2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC) Chemotherapy 1/13/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Targeted Therapy 1/14/2016 Herceptin (trastuzumab) Dx 2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+ Radiation Therapy Whole-breast: Breast Surgery Lumpectomy: Right Surgery Lumpectomy: Right
Log in to post a reply

Feb 14, 2019 04:24PM - edited Feb 15, 2019 05:00PM by Lumpie

'Remarkable' New Benefit in HER2+ Breast Cancer KATHERINE and T-DM1 Change Practice

https://www.medscape.com/viewarticle/909055?src=wn...

{More on the results of the KATHERINE trial - clearer coverage of some aspects of the trial, IMHO.}

The trial enrolled patients with stage I to III HER2-positive disease who were found to have residual disease upon excision after standard neoadjuvant treatment (chemotherapy plus a HER2-targeted drug). The trialists randomized these patients to post-surgery ado-trastuzumab emtansine (T-DM1; Kadcyla, Roche) or the current adjuvant standard — trastuzumab — for 14 cycles.

"We must be willing to let go of the life we have planned, so as to have the life that is waiting for us." "If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride." Dx 2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC) Chemotherapy 1/13/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Targeted Therapy 1/14/2016 Herceptin (trastuzumab) Dx 2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+ Radiation Therapy Whole-breast: Breast Surgery Lumpectomy: Right Surgery Lumpectomy: Right
Log in to post a reply

Feb 15, 2019 05:03PM Lumpie wrote:

Chocolate Fights Coughs Better Than Codeine, Says Science

https://www.coastalliving.com/food/chocolate-cures...

Good news for chocoholics. The next time you come down with a cough, just pop a piece of your favorite treat and you'll get all the cough-suppressing effects of codeine syrup without the fuzzy-headed side-effects. Here's how it works.

{To quote the contact who sent me this link "a friend sent me this article. I have prudently decided to accept the conclusion without evaluating the scientific evidence :) " Chocolate is my favorite therapy.}

"We must be willing to let go of the life we have planned, so as to have the life that is waiting for us." "If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride." Dx 2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC) Chemotherapy 1/13/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Targeted Therapy 1/14/2016 Herceptin (trastuzumab) Dx 2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+ Radiation Therapy Whole-breast: Breast Surgery Lumpectomy: Right Surgery Lumpectomy: Right
Log in to post a reply

Feb 15, 2019 05:16PM Lumpie wrote:

Cancer Drug Has Money-Back Guarantee — in China Palbociclib Refund Not Available in US

In China, Pfizer will reimburse up to 33% of the cost of its breast cancer drug palbociclib (Ibrance) if a patient's disease progresses within 4 months...

https://www.medscape.com/viewarticle/909138?src=wn...


"We must be willing to let go of the life we have planned, so as to have the life that is waiting for us." "If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride." Dx 2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC) Chemotherapy 1/13/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Targeted Therapy 1/14/2016 Herceptin (trastuzumab) Dx 2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+ Radiation Therapy Whole-breast: Breast Surgery Lumpectomy: Right Surgery Lumpectomy: Right
Log in to post a reply

Feb 15, 2019 05:25PM Lumpie wrote:

Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer and Outcomes Based on COX-2 Expression and ER Status

Celecoxib use during chemotherapy adversely affected survival in patients with breast cancer, and the effect was more marked in PTGS2-low and/or estrogen receptor-negative tumors. COX-2 inhibitors should preferably be avoided during docetaxel use in patients with breast cancer who are undergoing neoadjuvant chemotherapy (NAC).

Journal of Clinical Oncology

https://www.practiceupdate.com/C/79231/56?elsca1=e...

DOI: 10.1200/JCO.18.00636 Journal of Clinical Oncology


"We must be willing to let go of the life we have planned, so as to have the life that is waiting for us." "If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride." Dx 2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC) Chemotherapy 1/13/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Targeted Therapy 1/14/2016 Herceptin (trastuzumab) Dx 2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+ Radiation Therapy Whole-breast: Breast Surgery Lumpectomy: Right Surgery Lumpectomy: Right
Log in to post a reply

Feb 15, 2019 05:39PM Lumpie wrote:

Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer
  • Patients with stage II/III, ER-negative, HER2-positive breast cancer treated with four cycles of neoadjuvant pertuzumab and trastuzumab were followed to evaluate the correlation between early measurements of tumor maximum standardized uptake values corrected for lean body mass (SULmax) on PET/CT and pathologic complete response (pCR). Compared with patients who did not obtain pCR, those who did had a greater reduction in SULmax by day 15, a higher prevalence of SULmax reduction ≥40%, and a higher proportion of day 15 SULmax ≤3.
  • Early changes in SULmax predict the response to adjuvant pertuzumab/trastuzumab among patients with ER-negative, HER2-positive breast cancer. The use of this imaging strategy may eventually facilitate the use of targeted therapy.

Early changes in SULmax predict response to four cycles of PT in estrogen receptor-negative, HER2-positive breast cancer. Once optimized, this quantitative imaging strategy may facilitate a more tailored approach to therapy in this setting.

Journal of Clinical Oncology

https://www.practiceupdate.com/C/79480/56?elsca1=e...

DOI: 10.1200/JCO.2018.78.7986 Journal of Clinical Oncology

"We must be willing to let go of the life we have planned, so as to have the life that is waiting for us." "If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride." Dx 2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC) Chemotherapy 1/13/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Targeted Therapy 1/14/2016 Herceptin (trastuzumab) Dx 2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+ Radiation Therapy Whole-breast: Breast Surgery Lumpectomy: Right Surgery Lumpectomy: Right
Log in to post a reply

Feb 16, 2019 02:02AM Lumpie wrote:

Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine in Patients With Solid Tumors Receiving Chemotherapy
  • The authors of this phase II/III observer-blind, multicenter study report the immunogenicity and safety of the recombinant zoster vaccine (RZV) given to 232 patients with solid tumors before or at the initiation of a chemotherapy cycle. Patients given the RZV vaccine had higher postvaccination anti-gE antibody concentrations, gE-specific CD4+ T-cell frequencies, and vaccine response rates compared with patients given placebo. Adverse events occurred more frequently in the RZV group compared with the placebo group.
  • The use of RZV in patients with solid tumors receiving immunosuppressive chemotherapies was associated with a durable humoral and cell-mediated immune response without the development of any new safety concerns.
  • RZV was immunogenic in patients with STs receiving immunosuppressive chemotherapies. Humoral and cell-mediated immune responses persisted 1 year after vaccination. No safety concerns were identified.
  • data are emerging that RZV is both immunogenic and safe in solid tumor patients vaccinated before or during chemotherapy. If validated in other groups of immunocompromised patients, this would represent a significant advance in cancer care.
  • https://www.practiceupdate.com/content/immunogenic...
  • https://onlinelibrary.wiley.com/doi/full/10.1002/c...
  • https://doi.org/10.1002/cncr.31909
"We must be willing to let go of the life we have planned, so as to have the life that is waiting for us." "If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride." Dx 2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC) Chemotherapy 1/13/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Targeted Therapy 1/14/2016 Herceptin (trastuzumab) Dx 2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+ Radiation Therapy Whole-breast: Breast Surgery Lumpectomy: Right Surgery Lumpectomy: Right
Log in to post a reply

Feb 16, 2019 02:09AM Lumpie wrote:

Tucatinib With T-DM1 for HER2-Positive Metastatic Breast Cancer

Interview with Alison K Conlin MD Interview by Farzanna S Haffizulla MD, FACP, FAMWA

https://www.practiceupdate.com/content/tucatinib-w...

Re: a recent study looking at tucatinib in combination with T-DM1 for patients with HER2-positive breast cancer. Results were quite promising "both in the body and in central nervous system metastases."

"We must be willing to let go of the life we have planned, so as to have the life that is waiting for us." "If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride." Dx 2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC) Chemotherapy 1/13/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Targeted Therapy 1/14/2016 Herceptin (trastuzumab) Dx 2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+ Radiation Therapy Whole-breast: Breast Surgery Lumpectomy: Right Surgery Lumpectomy: Right
Log in to post a reply

Feb 16, 2019 02:31AM Lumpie wrote:

Impact of Metastatic Pattern on the Prognosis in Stage IV Breast Cancer at Initial Diagnosis
  • Using data from the SEER program from 2010 to 2013, this study evaluated 9143 women with stage IV breast cancer at initial diagnosis to determine factors associated with specific sites of metastases. Of these patients, 37.5% had bone metastases and a median overall survival of 38 months; 21.9% had visceral metastases and a median overall survival of 21 months; 28.8% had bone and visceral metastases and a median overall survival of 19 months; and 11.9% had other metastases and a median overall survival of 33 months. Older age, black race, grade 3/4 tumors, triple-negative disease, bone and visceral metastases, and an unmarried status were associated with significantly shorter overall survival. Patients with triple-negative and ER−/HER2+ disease were more likely to have brain, liver, lung, and other metastases, while patients with ER+/HER2+ disease were more likely to have liver metastases.
  • These findings demonstrate significant differences in survival based on specific sites of metastases that are influenced by tumor subtypes, which may be used to guide therapeutic choices for these patients.
  • https://www.practiceupdate.com/content/impact-of-m...
  • https://link.springer.com/article/10.1007%2Fs10549...
  • Leone, B.A., Vallejo, C.T., Romero, A.O. et al. Breast Cancer Res Treat (2017) 161: 537. https://doi.org/10.1007/s10549-016-4066-7
"We must be willing to let go of the life we have planned, so as to have the life that is waiting for us." "If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride." Dx 2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC) Chemotherapy 1/13/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Targeted Therapy 1/14/2016 Herceptin (trastuzumab) Dx 2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+ Radiation Therapy Whole-breast: Breast Surgery Lumpectomy: Right Surgery Lumpectomy: Right
Log in to post a reply

Feb 16, 2019 04:26AM Lumpie wrote:

Everolimus/Lapatinib/Capecitabine Is Effective and Safe for HER2+ Breast Cancer With Brain Metastases
  • Results of this study demonstrate the tolerability of the combination of everolimus, lapatinib, and capecitabine in heavily pretreated patients with HER2-positive disease and brain metastasis.
"We must be willing to let go of the life we have planned, so as to have the life that is waiting for us." "If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride." Dx 2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC) Chemotherapy 1/13/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Targeted Therapy 1/14/2016 Herceptin (trastuzumab) Dx 2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+ Radiation Therapy Whole-breast: Breast Surgery Lumpectomy: Right Surgery Lumpectomy: Right
Log in to post a reply

Feb 19, 2019 11:24AM - edited Feb 19, 2019 11:24AM by marijen

New cell-tracking technique sheds light on breast cancer spread

Barcoding reveals complex clonal behavior in patient-derived xenografts of metastatic triple negative breast cancer | Nature Communications


https://www.medicalnewstoday.com/articles/324477.p...


https://www.nature.com/articles/s41467-019-08595-2

Log in to post a reply

Feb 20, 2019 02:04AM - edited Feb 20, 2019 02:05AM by marijen

Christina Bennett, MS

November 28, 2018 Statins Repurposed to Slow Proliferation in Metastatic Breast Cancer Cells



The findings suggest the consideration of long-term use of statins for patients with breast cancer.

Statins were shown to slow proliferation in metastatic breast cancer cells but not primary tumor cells, suggesting the long-term use of statins in the adjuvant setting should be considered for patients with breast cancer.1 Statins have been found to reduce mortality in patients with breast cancer, but the mechanism by which statins influence mortality without affecting the growth of the primary tumor has been unclear. The study results were recently published in the British Journal of Cancer.

To elucidate the effect of statins on metastatic cell proliferation, study researchers created several models to mimic breast cancer metastasis. In vitro and ex vivo models were created to mimic breast cancer metastasis to the liver. The in vitro model was a 2-dimensional coculture, and the ex vivo model was a 3-dimensional microphysiological system. Two independent mouse models were created to mimic spontaneous breast cancer metastasis to the lung and liver.

Statins were shown in each model to "directly affect the proliferation of breast cancer cells, specifically at the metastatic site," the study authors wrote. In the in vitro model, atorvastatin slowed proliferation of mesenchymal but not epithelial breast cancer cells. When dormant breast cancer cells were stimulated in the 3-dimensional ex vivo microphysiological system, atorvastatin inhibited their emergence. In both mouse models, statins slowed proliferation of metastatic cells but not primary tumor cells.

RELATED ARTICLES

"As statins can block metastatic tumor outgrowth, they should be considered for use as long-term adjuvant drugs to delay clinical emergence and decrease mortality in breast cancer patients," the study authors concluded.

Reference

  1. Beckwitt CH, Clark AM, Ma B, Whaley D, Oltvai ZN, Wells A. Statins attenuate outgrowth of breast cancer metastases. Br J Cancer. 2018;119(9):1094-1105. doi: 10.1038/s41416-018-0267-7
Log in to post a reply

Feb 20, 2019 06:32PM Lumpie wrote:

p, p'-DDT Exposure Linked to Breast Cancer Through Age 54

Risk for breast cancer varies based on timing of first exposure, age at diagnosis

"Considering the patterns we observed, working backward to determine when a woman first came into contact with the chemical could help inform early detection and treatment of DDT-associated breast cancer,"

study published online Feb. 13 {2019} in the Journal of the National Cancer Institute.

"We must be willing to let go of the life we have planned, so as to have the life that is waiting for us." "If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride." Dx 2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC) Chemotherapy 1/13/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Targeted Therapy 1/14/2016 Herceptin (trastuzumab) Dx 2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+ Radiation Therapy Whole-breast: Breast Surgery Lumpectomy: Right Surgery Lumpectomy: Right
Log in to post a reply

Feb 20, 2019 07:05PM - edited Feb 20, 2019 07:17PM by Lumpie

Researchers Develop Therapy to Fight Blood Clots and Cancer Metastasis A preclinical study of deactivated platelets promises new approach to treating diseases.

https://gwtoday.gwu.edu/researchers-develop-therap...

A new reversible, drug-free antiplatelet therapy could reduce the risk of blood clots and potentially prevent the spread of cancer cells from a primary site to different parts of the body—or cancer metastasis, according to a study published Wednesday in Science Translational Medicine.

"our results suggest that platelet decoys might represent an effective strategy for obtaining antithrombotic and antimetastatic effects."

http://stm.sciencemag.org/content/11/479/eaau5898

DOI: 10.1126/scitranslmed.aau5898

"We must be willing to let go of the life we have planned, so as to have the life that is waiting for us." "If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride." Dx 2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC) Chemotherapy 1/13/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Targeted Therapy 1/14/2016 Herceptin (trastuzumab) Dx 2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+ Radiation Therapy Whole-breast: Breast Surgery Lumpectomy: Right Surgery Lumpectomy: Right
Log in to post a reply

Feb 20, 2019 08:16PM Lumpie wrote:

Influence of Adjuvant Systemic Regimens on Contralateral Breast Cancer Risk and Receptor Subtype
  • This population-based cohort study was designed to evaluate the influence of various systemic treatment regimens on the subtype-specific risk of contralateral breast cancer (CBC). The 10-year cumulative incidence of CBC was 3.8%. Endocrine therapy, adjuvant chemotherapy, and trastuzumab with chemotherapy were associated with a reduced risk of CBC. Taxane-containing chemotherapy and aromatase inhibitors were associated with the largest reduction in CBC risk.
  • The risk of CBC is reduced in association with endocrine therapy, chemotherapy, and trastuzumab with chemotherapy, and each regimen has varying effects on CBC subtypes. The biggest reduction in risk is seen following treatment with taxane-containing chemotherapy and aromatase inhibitors.
  • Of 83,144 BC patients, 2,816 developed a CBC; the 10-year cumulative incidence was 3.8%
https://www.practiceupdate.com/C/79332/56?elsca1=e...
https://academic.oup.com/jnci/advance-article-abst...
https://doi.org/10.1093/jnci/djz010
"We must be willing to let go of the life we have planned, so as to have the life that is waiting for us." "If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride." Dx 2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC) Chemotherapy 1/13/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Targeted Therapy 1/14/2016 Herceptin (trastuzumab) Dx 2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+ Radiation Therapy Whole-breast: Breast Surgery Lumpectomy: Right Surgery Lumpectomy: Right
Log in to post a reply

Feb 20, 2019 09:11PM Lumpie wrote:

Broad Institute targets blood-draw diagnostics

FEBRUARY 19, 2019

With pledges of $25 million, the nonprofit Broad Institute of MIT and Harvard plans to announce Tuesday that it's creating a new center to develop a diagnostic test to pinpoint how well cancer patients respond to treatment through a simple blood draw.

Louis V. Gerstner Jr., the former CEO of IBM who chairs the institute's board of directors, has committed $15 million to the Gerstner Center for Cancer Diagnostics at the Broad. The center will receive an additional $10 million from the Eli and Edythe Broad Foundation.

The center is pursuing a goal that some other biotech companies in the United States are also chasing: developing a sensitive blood-based biopsy to speed cancer detection.

Although many aspects of cancer treatment have improved dramatically in recent years, diagnostic tests have lagged, according to Broad officials. Today, doctors still rely on a biopsy of a tumor obtained through surgery or have the patient undergo a CT or MRI scan. Surgical biopsies are invasive, of course, and the other tests provide no molecular insights.

The Gerstner Center will focus on developing a blood biopsy that would monitor a patient's response to chemotherapy, radiation, or immunotherapy with molecular precision. Broad scientists hope the test would identify small numbers of cancer cells that remain in patients who have been treated and may cause a relapse years or even decades later.

"Not long ago, I thought that blood biopsy was more science fiction than reality," said Dr. Todd Golub, a cancer specialist who works as Broad's chief scientific officer and will head the Gerstner Center. "In fact, Broad scientists have demonstrated that it's possible to look at an entire cancer genome from a blood biopsy. That is spectacular."

The new center will work with technology experts, cancer biologists, computational scientists, and clinicians.

By Jonathan Saltzman

https://www.bostonglobe.com/business/2019/02/19/br...

"We must be willing to let go of the life we have planned, so as to have the life that is waiting for us." "If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride." Dx 2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC) Chemotherapy 1/13/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Targeted Therapy 1/14/2016 Herceptin (trastuzumab) Dx 2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+ Radiation Therapy Whole-breast: Breast Surgery Lumpectomy: Right Surgery Lumpectomy: Right
Log in to post a reply

Feb 20, 2019 10:25PM Lumpie wrote:

Cancer treatment at home is safe, effective, and closer to happening than you think

Imagine having cancer and being told that most of your treatment will happen in your home instead of a high-tech cancer center. That may sound preposterous, but it's closer to happening than you might think.

The cancer care at home model could become a reality...

It's time to reimagine the role of hospitals and outpatient clinics in cancer care. Rather than being the routine site of care, hospitals and outpatient clinics should be reserved for the minority of cancer patients who require treatments that only hospitals and clinics can give. People with cancer will thank us for this change, from the comfort of their homes.

https://www.statnews.com/2019/02/06/cancer-treatme...


"We must be willing to let go of the life we have planned, so as to have the life that is waiting for us." "If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride." Dx 2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC) Chemotherapy 1/13/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Targeted Therapy 1/14/2016 Herceptin (trastuzumab) Dx 2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+ Radiation Therapy Whole-breast: Breast Surgery Lumpectomy: Right Surgery Lumpectomy: Right
Log in to post a reply

Feb 20, 2019 10:38PM - edited Feb 20, 2019 10:38PM by Lumpie

People diagnosed with cancer often don't embrace the term 'survivor'

"Cancer survivor" has become a catch-all phrase to refer to living individuals diagnosed with cancer at some point in their lives. Cancer clinics and clinicians, patient advocacy organizations and media reportscommonly use the term.

Should the same term be used for the entire spectrum of living people who have experienced cancer, which represents more than 100 distinct diseases affecting approximately 14 million people in the United States?

An analysis of 23 studies of how people diagnosed with cancer view the term "cancer survivor" shows that although many embrace it, others see it as inappropriate.

Language used with and about patients is important and can cause needless distress when used without care.

Conclusions: Using the blanket term "survivor" to label a diverse group is problematic; although the term offers a positive identity for some, others reject it or find it offensive, at least for patients like those represented in this study. If cancer patients are going to be labeled, they should choose the one that is most empowering and reflective of their experience.

https://theconversation.com/people-diagnosed-with-...

https://www.tandfonline.com/doi/abs/10.1080/073473...

"We must be willing to let go of the life we have planned, so as to have the life that is waiting for us." "If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride." Dx 2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC) Chemotherapy 1/13/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Targeted Therapy 1/14/2016 Herceptin (trastuzumab) Dx 2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+ Radiation Therapy Whole-breast: Breast Surgery Lumpectomy: Right Surgery Lumpectomy: Right
Log in to post a reply

Feb 21, 2019 11:23AM Lumpie wrote:

Increasing the Dose Intensity of Chemotherapy by More Frequent Administration or Sequential Scheduling
The Lancet
  • This meta-analysis was designed to compare the impact of dose-intense versus standard-schedule chemotherapy for patients with early breast cancer. The risk of recurrence at 10 years was lower in the dose-intense group compared with the standard-schedule group (28.0% vs 31.4%; P<.0001). Both 10-year breast cancer mortality and all-cause mortality were also significantly lower in the dose-intense group compared with the standard-schedule group.
"We must be willing to let go of the life we have planned, so as to have the life that is waiting for us." "If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride." Dx 2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC) Chemotherapy 1/13/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Targeted Therapy 1/14/2016 Herceptin (trastuzumab) Dx 2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+ Radiation Therapy Whole-breast: Breast Surgery Lumpectomy: Right Surgery Lumpectomy: Right
Log in to post a reply

Feb 21, 2019 11:29AM Lumpie wrote:

Pembrolizumab Plus Trastuzumab in Trastuzumab-Resistant, Advanced HER2-Positive Breast Cancer PANACEA: a single-arm, multicentre, phase 1b–2 trial
The Lancet Oncology
TAKE-HOME MESSAGE
  • This phase Ib/II trial was designed to evaluate the activity of pembrolizumab plus trastuzumab among patients with trastuzumab-resistant advanced HER2-positive breast cancer. In the phase II cohort, there was an objective response rate of 15% among PD-L1–positive patients but no responses in PD-L1–negative patients.
  • Pembrolizumab plus trastuzumab appears to have some activity against PD-L1–positive, HER2-positive breast cancer, and further studies are needed to confirm these findings.
  • HER2-positive breast cancers usually contain large amounts of T-cell infiltrate. We hypothesised that trastuzumab resistance in HER2-positive breast cancer could be mediated by immune mechanisms. We assessed the safety and anti-tumour activity of pembrolizumab, a programmed cell death protein 1 (PD-1) inhibitor, added to trastuzumab in trastuzumab-resistant, advanced HER2-positive breast cancer.
  • Pembrolizumab plus trastuzumab was safe and showed activity and durable clinical benefit in patients with PD-L1-positive, trastuzumab-resistant, advanced, HER2-positive breast cancer. Further studies in this breast cancer subtype should focus on a PD-L1-positive population and be done in less heavily pretreated patients.
  • https://www.practiceupdate.com/C/79904/56?elsca1=e...
  • https://www.thelancet.com/journals/lanonc/article/...(18)30812-X/fulltext
  • DOI:https://doi.org/10.1016/S1470-2045(18)30812-X
"We must be willing to let go of the life we have planned, so as to have the life that is waiting for us." "If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride." Dx 2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC) Chemotherapy 1/13/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Targeted Therapy 1/14/2016 Herceptin (trastuzumab) Dx 2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+ Radiation Therapy Whole-breast: Breast Surgery Lumpectomy: Right Surgery Lumpectomy: Right
Log in to post a reply

Feb 21, 2019 11:38PM Traveltext wrote:

CONCLUSION

“Compared with women, men with HR+/HER2+ tumors had twice the risk of death.

https://journals.lww.com/amjclinicaloncology/Abstract/2019/02000/Overall_Survival_of_Men_and_Women_With_Breast.18.aspx

Objectives: To analyze differences in overall survival(OS) between male breast cancer (MBC) and female breast cancer (FBC) according to tumor subtype compared with other factors.

Materials and Methods: We evaluated men and women with breast cancer between 2010 and 2013 with known hormone receptor (HR) status and human epidermal growth factor receptor 2 (HER2) status reported to the National Cancer Institute's Surveillance, Epidemiology, and End Results program. Patient characteristics were compared between groups. Univariate and multivariate analyses were performed to determine the effect of each variable on OS. Breast cancer–specific survival was a secondary endpoint.

Results: We included 1187 MBC and 166,054 FBC. Median follow-up was 21 months (range, 1 to 48) for both groups. OS at 3 years for MBC and FBC was 85.6% and 90.4%, respectively (P=0.0002). MBC were more ductal, had higher grade, presented with more advanced stage and were often HR+/HER2− (each P<0.0001). MBC had worse OS than FBC in HR+/HER2− (Hazard ratio [HaR], 1.5; P=0.0005), HR+/HER2+ (HaR, 2.8; P<0.0001) and triple negative (HaR, 4.3; P<0.0001) (P interaction<0.02). MBC had significantly worse OS than FBC in stages I and II, but similar OS in stages III and IV (P interaction<0.01). In multivariate analysis, HR+/HER2+ was the only subtype with significant differences in OS between MBC and FBC (HaR, 2.0; P=0.002).

Conclusions: OS was significantly different in both groups. Men had worse OS in early stages while similar OS in stages III and IV. There were significant differences in OS according to tumor subtype; compared with women, men with HR+/HER2+ tumors had twice the risk of death.

NED breast and prostate cancer. More on Male BC

Dx 03/14, IBC, Lgth. 2cm, Stge IIIB, Gde 2B, ER+/PR+, HER2- ; FEC x3, Taxol x3; Mx & 2/23 nodes; Rads x 33; now on tamoxofin.

Log in to post a reply

Feb 22, 2019 12:59PM Lumpie wrote:

Oncotype DX Not Cost-Effective for Low-Risk Breast Cancer

Incremental cost-effectiveness ratio varies across clinical risk groups, sensitive to patient age

The multigene expression test Oncotype DX (ODX) is not cost-effective for women with breast cancer who are at low risk for recurrence, according to research published online Jan. 22 in the Journal of the National Comprehensive Cancer Network.

"ODX is not cost-effective for women with clinical low-risk breast cancer, which constitutes most patients with ER-positive disease," the authors write.

https://www.practiceupdate.com/C/80064/56?elsca1=e...

http://www.jnccn.org/content/17/1/39.full?sid=4a3a...

doi:10.6004/jnccn.2018.7077

"We must be willing to let go of the life we have planned, so as to have the life that is waiting for us." "If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride." Dx 2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC) Chemotherapy 1/13/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Targeted Therapy 1/14/2016 Herceptin (trastuzumab) Dx 2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+ Radiation Therapy Whole-breast: Breast Surgery Lumpectomy: Right Surgery Lumpectomy: Right
Log in to post a reply

Feb 22, 2019 01:09PM Lumpie wrote:

Hepatic Arterial Therapy With Oxaliplatin and Systemic Capecitabine for Liver Metastases From Breast Cancer
  • The authors report the results of two phase II trials investigating the combination of capecitabine and oxaliplatin in patients with breast cancer and liver metastases. Among the 52 patients, the response rate was 42.3%, including 7.7% complete responses and 34.6% partial responses. The median progression-free survival was 10.8 months. The most frequently reported grade 3 adverse events were hand–foot syndrome, neuropathy, fatigue, and abdominal pain.
  • The results demonstrate that the combination of capecitabine and oxaliplatin is effective and well-tolerated in patients with breast cancer liver metastases.
Commentary by Lillie D Shockney RN, BS, MAS

One challenge of a patient who has liver metastasis is that she needs her liver to be metabolizing properly in order for chemotherapy—really any systemic treatments—to work as intended. The approach reported here appears to bypass the usual method of administration, and the drug is placed directly in the liver itself. The numbers are small, but the results are promising. The treatment schedule can be tricky and will require close monitoring, follow-up, and specific points of contact throughout the treatment process.

These women are paving the ways for future women diagnosed after them. {Gratuitous comment by poster: Many of us are grateful!}

https://www.practiceupdate.com/c/77978/67/13/?elsc...
https://www.thebreastonline.com/article/S0960-9776(18)30331-X/fulltext
DOI: https://doi.org/10.1016/j.breast.2018.12.002

"We must be willing to let go of the life we have planned, so as to have the life that is waiting for us." "If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride." Dx 2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC) Chemotherapy 1/13/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Targeted Therapy 1/14/2016 Herceptin (trastuzumab) Dx 2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+ Radiation Therapy Whole-breast: Breast Surgery Lumpectomy: Right Surgery Lumpectomy: Right
Log in to post a reply

Feb 22, 2019 01:13PM Lumpie wrote:

The role of histone deacetylase inhibitors in metastatic breast cancer

{This sounds fairly cutting edge and technical, but for those who like to be ahead of the curve/keep up with the latest research, I thought I would put this early report out there....}

Histone deacetylase inhibitors (HDACi) are a relatively new class of drug that plays an important role in the epigenetic and non-epigenetic regulation in cancer, inducing death, apoptosis and cell cycle arrest in cancer cells. Although HDACi are approved only for hematologic malignancies, there are several trials in the breast cancer setting with promising results. In this review, we summarize the latest studies with HDACi in breast cancer from the emerging data in the translational research until its possible applicability in the clinical practice.

https://www.practiceupdate.com/c/77977/67/13/?elsc...

https://www.thebreastonline.com/article/S0960-9776(18)30330-8/fulltext

DOI: https://doi.org/10.1016/j.breast.2018.12.001

{This is a pay-per-article unless you have access to a research database.}

"We must be willing to let go of the life we have planned, so as to have the life that is waiting for us." "If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride." Dx 2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC) Chemotherapy 1/13/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Targeted Therapy 1/14/2016 Herceptin (trastuzumab) Dx 2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+ Radiation Therapy Whole-breast: Breast Surgery Lumpectomy: Right Surgery Lumpectomy: Right
Log in to post a reply

Feb 22, 2019 01:15PM Lumpie wrote:

The role of histone deacetylase inhibitors in metastatic breast cancer

{This sounds fairly cutting edge and technical, but for those who like to be ahead of the curve/keep up with the latest research, I thought I would put this early report out there....}

Histone deacetylase inhibitors (HDACi) are a relatively new class of drug that plays an important role in the epigenetic and non-epigenetic regulation in cancer, inducing death, apoptosis and cell cycle arrest in cancer cells. Although HDACi are approved only for hematologic malignancies, there are several trials in the breast cancer setting with promising results. In this review, we summarize the latest studies with HDACi in breast cancer from the emerging data in the translational research until its possible applicability in the clinical practice.

https://www.practiceupdate.com/c/77977/67/13/?elsc...

https://www.thebreastonline.com/article/S0960-9776(18)30330-8/fulltext

DOI: https://doi.org/10.1016/j.breast.2018.12.001

{This is a pay-per-article unless you have access to a research database.}

"We must be willing to let go of the life we have planned, so as to have the life that is waiting for us." "If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride." Dx 2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC) Chemotherapy 1/13/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Targeted Therapy 1/14/2016 Herceptin (trastuzumab) Dx 2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+ Radiation Therapy Whole-breast: Breast Surgery Lumpectomy: Right Surgery Lumpectomy: Right
Log in to post a reply

Feb 22, 2019 05:41PM Lumpie wrote:

'Not Letting It Define Us' — Walking The Runway With Metastatic Breast Cancer

https://www.npr.org/sections/health-shots/2019/02/...

{This isn't technically research news but I thought some people might be interested in this news coverage of MBC....}

....This was the third annual #Cancerland fashion show, put on by METAvivor, a nonprofit organization that supports research and awareness of metastatic breast cancer, along with lingerie company, AnaOno. The goal: Raise funds for research to improve treatment for metastatic disease, while changing public perception of the condition.

"We must be willing to let go of the life we have planned, so as to have the life that is waiting for us." "If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride." Dx 2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC) Chemotherapy 1/13/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Targeted Therapy 1/14/2016 Herceptin (trastuzumab) Dx 2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+ Radiation Therapy Whole-breast: Breast Surgery Lumpectomy: Right Surgery Lumpectomy: Right
Log in to post a reply

Feb 23, 2019 09:16PM marijen wrote:

New recommendations say not all women need genetic testing for cancer. Critics say it could cost lives
CNN

Primary care providers should screen women for personal, family and/or ethnic history of breast, ovarian, tubal or peritoneal cancer to decide who should undergo genetic counseling for BRCA1 and BRCA2 mutations, the US Preventive Services Task Force recommended Tuesday. The mutations increase a woman's cancer risk. Read the full story

Shared from Apple News

Page 29 of 32 (935 results)